ReviewAnnals of medicine2025
Sestrins: a new therapeutic target for endothelial dysfunction and cardiovascular disease prevention.
Review in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total Flavonoids from Snow Chrysanthemum Exert Synergistic Vascular and Neuroprotective Effects in Hypertensive Vascular Dementia Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSestrins are a highly conserved family of proteins that have garnered significant attention for their critical roles in regulating cellular stress responses, antioxidative defense, energy metabolism, and cell survival. Endothelial dysfunction, a pivotal early event in the development of cardiovascular diseases (CVDs), is strongly associated with oxidative stress, inflammation, and disruption of vascular homeostasis.
findingsRecent studies have demonstrated that Sestrins contribute to maintaining endothelial cell integrity by mitigating oxidative stress, modulating inflammatory signaling, and promoting cellular adaptation through the regulation of key pathways such as AMPK/mTOR and autophagy. Experimental evidence from cardiovascular disease models suggests that upregulation of Sestrins can improve endothelial function and attenuate vascular damage, highlighting their involvement in vascular protection and disease modulation.
conclusionsSestrins emerge as promising therapeutic targets for the prevention and treatment of endothelial dysfunction and cardiovascular diseases. This review underscores the potential of Sestrins in vascular biology and advocates for further research to elucidate their mechanisms and clinical applicability in cardiovascular medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.